NA-Selank
Anxiolytic, Cognition
Uses native Selank's ~0.5 h plasma half-life as a stand-in. No pharmacokinetics have been published for the N-acetylated form; acetylation exists to slow aminopeptidase breakdown, so the real value is likely longer. Treat this curve as a conservative floor, not a measurement.
In short
- An N-acetylated analogue of Selank, sold on a longer-duration claim.
- No pharmacokinetic study of the N-acetyl form exists — the "2-3x longer" figure is a vendor estimate.
- All cited clinical evidence belongs to native Selank, a different molecule.
- Native Selank is registered in Russia as an anxiolytic; this derivative is registered nowhere.
- Evidence for the N-acetyl form specifically is thinner than for native Selank, which is itself thin outside Russia.
Structure
An N-acetylated (and often amidated) analogue of Selank. PubChem has no entry under this research-market name. See the Selank entry for the parent peptide.
How it works
Selank is a synthetic analogue of tuftsin, an immunomodulatory tetrapeptide fragment of IgG, extended with a Pro-Gly-Pro tail for stability.
Proposed mechanisms include indirect modulation of GABA-A receptor expression without binding the benzodiazepine site, effects on serotonergic and noradrenergic systems, BDNF upregulation, and influence on enkephalin-degrading enzymes.
N-acetylation is intended to further slow aminopeptidase degradation. The same caveat as NA-Semax applies: the chemistry is sound in principle, and whether it preserves activity while extending duration has not been measured.
What the research shows
The anxiolytic results cited — including comparisons against benzodiazepines for tolerability — come from Russian studies of native Selank.
No trial of the N-acetylated form has been published.
Reports of greater potency or duration are anecdotal.
Dosing in the literature
Figures below are quoted from published studies, with the species or population they were measured in. They are records of what was studied, not recommendations.
No published dosing data for this compound.
Commonly reported ranges
These are amounts people report using. They are not from any study, have not been evaluated for safety, and are reproduced here only because they circulate widely and are better seen alongside the evidence than instead of it.
| Reported by | Amount | Route |
|---|---|---|
| Commonly reported | 250–750 µg daily, divided | intranasal |
No published human pharmacokinetic study establishes a dose, interval, or duration for this compound. Community figures below have no trial behind them and are reports of practice, not evidence. No study has used this compound, so there is no literature dosing. Community figures derive from native Selank protocols.
Handling and storage
Typically supplied lyophilised for reconstitution into nasal drops or spray, refrigerated after mixing.
Intranasal is the route with evidence behind it for the parent compound. Injection has no supporting data.
Side effects
No safety data exists for the N-acetylated form.
Native Selank is reported well tolerated in Russian clinical use, with nasal irritation most common, and notably without the sedation, withdrawal, or dependence associated with benzodiazepines.
Whether that profile transfers to a modified molecule is untested.
Combinations
Commonly paired with NA-Semax. No study has evaluated the combination in either the native or modified forms.
No interaction data exists with conventional anxiolytics or antidepressants.
Research status
The research is on native Selank, from the Institute of Molecular Genetics in Moscow, largely untranslated and unreplicated.
The N-acetylated derivative has no independent research base.
Legal status
Not approved anywhere. Native Selank is registered in Russia; this derivative is not. Sold for research use only.
WADA status
Not specifically named on the Prohibited List. Falls under WADA class S0, which prohibits any pharmacological substance not currently approved by any governmental regulatory health authority for human therapeutic use. Treat it as prohibited in sport.
Conclusion
NA-Selank stands in the same relationship to Selank as NA-Semax does to Semax: a plausible chemical modification, a marketing claim about duration that nobody has measured, and none of the parent compound's clinical record.
Sources
Track your own NA-Selank protocol
Peppers logs your doses, models your levels from this half-life, tracks your vials and tells you when you will run out. Free on iPhone.
Reference and educational information only. Not medical advice. Nothing here diagnoses, treats, or prescribes, and nothing here is a recommendation to use any compound. The compounds described are research chemicals and are not approved for human consumption. Legal and anti-doping status change — the review date above is when these claims were last checked. Talk to a qualified clinician about anything you intend to take.